Synaptogenix Company Insiders
| SNPX Stock | USD 2.72 0.01 0.37% |
Synaptogenix's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Synaptogenix suggests that vertually all insiders are panicking. Synaptogenix employs about 5 people. The company is managed by 3 executives with a total tenure of roughly 12 years, averaging almost 4.0 years of service per executive, having 1.67 employees per reported executive.
Synaptogenix's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2022-12-16 | William S Singer | Disposed 1080 @ 29.25 | View |
Monitoring Synaptogenix's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Synaptogenix |
Synaptogenix Management Team Effectiveness
The company has return on total asset (ROA) of (0.1382) % which means that it has lost $0.1382 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.075) %, meaning that it created substantial loss on money invested by shareholders. Synaptogenix's management efficiency ratios could be used to measure how well Synaptogenix manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.2 in 2024. Return On Capital Employed is likely to drop to -0.33 in 2024. Non Current Assets Total is likely to rise to about 610 K in 2024, whereas Total Assets are likely to drop slightly above 28.6 M in 2024.Common Stock Shares Outstanding is likely to drop to about 442.8 K in 2024. Net Loss is likely to drop to about (6.9 M) in 2024
Synaptogenix Workforce Comparison
Synaptogenix is rated fifth in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 49.0. Synaptogenix retains roughly 5.0 in number of employees claiming about 10% of equities under Health Care industry.
Synaptogenix Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Synaptogenix insiders, such as employees or executives, is commonly permitted as long as it does not rely on Synaptogenix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Synaptogenix insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tuchman Alan J few days ago Acquisition by Tuchman Alan J of 112000 shares of Synaptogenix subject to Rule 16b-3 | ||
Schechter Jonathan over three months ago Disposition of tradable shares by Schechter Jonathan of Synaptogenix subject to Rule 16b-3 | ||
Silverman Joshua over three months ago Disposition of tradable shares by Silverman Joshua of Synaptogenix subject to Rule 16b-3 | ||
Silverman Joshua over three months ago Disposition of 19012 shares by Silverman Joshua of Synaptogenix at 1.1719 subject to Rule 16b-3 | ||
Robert Weinstein over three months ago Acquisition by Robert Weinstein of 96000 shares of Synaptogenix subject to Rule 16b-3 | ||
Silverman Joshua over six months ago Acquisition by Silverman Joshua of 800 shares of Synaptogenix at 5. subject to Rule 16b-3 | ||
Bernstein Bruce over six months ago Acquisition by Bernstein Bruce of 800 shares of Synaptogenix at 5. subject to Rule 16b-3 | ||
Bernstein Bruce over a year ago Acquisition by Bernstein Bruce of 20000 shares of Synaptogenix subject to Rule 16b-3 |
Synaptogenix Notable Stakeholders
A Synaptogenix stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Synaptogenix often face trade-offs trying to please all of them. Synaptogenix's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Synaptogenix's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
About Synaptogenix Management Performance
The success or failure of an entity such as Synaptogenix often depends on how effective the management is. Synaptogenix management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Synaptogenix management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Synaptogenix management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.19) | (0.20) | |
| Return On Capital Employed | (0.31) | (0.33) | |
| Return On Assets | (0.19) | (0.20) | |
| Return On Equity | (0.25) | (0.26) |
Please note, the imprecision that can be found in Synaptogenix's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Synaptogenix. Check Synaptogenix's Beneish M Score to see the likelihood of Synaptogenix's management manipulating its earnings.
Synaptogenix Workforce Analysis
Traditionally, organizations such as Synaptogenix use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Synaptogenix within its industry.Synaptogenix Manpower Efficiency
Return on Synaptogenix Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 2M | |
| Working Capital Per Employee | 5.3M | |
| Working Capital Per Executive | 8.8M |
Additional Tools for Synaptogenix Stock Analysis
When running Synaptogenix's price analysis, check to measure Synaptogenix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synaptogenix is operating at the current time. Most of Synaptogenix's value examination focuses on studying past and present price action to predict the probability of Synaptogenix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synaptogenix's price. Additionally, you may evaluate how the addition of Synaptogenix to your portfolios can decrease your overall portfolio volatility.